Abstract Number: 0446 • ACR Convergence 2021
Clinical Characteristics, Including History of Myocardial Infarction and Stroke, Among US PMO Women Initiating Treatment with Romosozumab and Other Anti-osteoporosis Therapies
Background/Purpose: This study is an ongoing USFDA post-marketing requirement (2020-2024) to assess the impact of boxed warning on romosozumab (romo) treatment and the feasibility of…Abstract Number: 1915 • ACR Convergence 2021
Risk of Cardiovascular Outcomes with Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis
Background/Purpose: Many guidelines recommend limiting glucocorticoids to short-term use in patients with rheumatoid arthritis (RA), but up to 40% of patients remain on glucocorticoids long-term.…Abstract Number: 0409 • ACR Convergence 2020
Clinical Characteristics, Brain MRI Findings, and Diagnostic Approach of the Central Nervous System Vasculitis by Affected Vessel Size
Background/Purpose: Diagnosis of the central nervous system vasculitis (CNS-V) is made on the basis of image findings or brain biopsy. Recently, two different subtypes of…Abstract Number: 0411 • ACR Convergence 2020
Serial Vessel Wall Enhancement Change on High-Resolution MRI Vessel Wall Imaging in Primary Central Nervous System Vasculitis
Background/Purpose: High-resolution vessel wall imaging (HR-VWI) is emerging as a tool of notable utility in the diagnosis of central nervous system vasculitis (CNS-V). However, little…Abstract Number: 0433 • ACR Convergence 2020
Racial Disparities and New SLE-Specific Predictors of Stroke and Ischemic Heart Disease in Patients with Lupus
Background/Purpose: In the US, cardiovascular disease (CVD) is the leading cause of disparities in life expectancy between black and white populations. We recently reported a…Abstract Number: 1278 • ACR Convergence 2020
Does Co-existing Systemic Lupus Erythematosus Affect Outcomes of Hospitalizations for Ischemic Stroke?
Background/Purpose: Various studies have shown that individuals with Systemic Lupus Erythematosus (SLE) have a higher risk of stroke and cerebrovascular events than the general population. These events represent a significant…Abstract Number: 1630 • ACR Convergence 2020
Long-term Safety of Tildrakizumab in Patients with Moderate to Severe Plaque Psoriasis: Incidence of Confirmed Major Adverse Cardiovascular Events Through 3 Years (148 Weeks) from Two Phase 3 Trials
Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody that is approved for the treatment of moderate to severe plaque psoriasis. The objective of this…
ACR Meeting Abstracts